Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arvinas Holding Company (ARVN)
NASDAQ:ARVN
RESEARCH TOOLSreports
Earnings Data
Report Date
May 06, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-1.02Last Year’s EPS
-0.97Same Quarter Last Year
Strong Buy
Based on 16 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 11, 2025
|% Change Since: -3.16%
|Next Earnings Date:May 06, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive outlook for Arvinas, with strong financial results, significant pipeline advancements, and strategic initiatives in place for future growth. Although there are some challenges, such as increased expenses and a leadership change, the overall progress and strategic positioning outweigh these concerns.Company Guidance
During the Arvinas Fourth Quarter 2024 Earnings Conference Call, the company provided extensive guidance on its pipeline and financial outlook. Key metrics highlighted include the anticipation of the first Phase 3 topline results for the VERITAC-2 trial expected later this quarter, which will be pivotal for submitting a new drug application. The company is advancing its vepdegestrant (vepdeg) program with plans to initiate Phase 3 trials in first-line and second-line settings in 2025, in collaboration with Pfizer. Financially, Arvinas reported $263.4 million in revenue for 2024, with a strong cash position of over $1 billion, sufficient to support operations into 2027. Additionally, the company aims to present first-in-human data from its ARV-102 LRRK2 degrader in April, marking significant progress in their neuroscience pipeline. Arvinas also plans to file an investigational new drug application for its KRAS G12D degrader this year, indicating robust development activities across oncology and neuroscience.Strong Financial Position
Arvinas is in a strong financial position with over $1 billion in cash, cash equivalents, and marketable securities, sufficient to support operations into 2027.
Significant Revenue Growth
Revenue for Q4 2024 was $59.2 million, a major increase compared to a negative $43.1 million in Q4 2023. The full year 2024 revenue was $263.4 million, up from $78.5 million in 2023.
Advancement of Vepdegestrant Program
Phase 3 topline data from VERITAC-2 expected this quarter, with plans for two additional Phase 3 combination trials in 2025.
Progress in Neuroscience Program
ARV-102, a LRRK2 degrader, shows promise in early trials with data to be presented at the AD/PD conference.
Pipeline Expansion
Plans to file an investigational new drug application for KRAS G12D degrader, with ongoing progress in BCL6 degrader and other PROTAC programs.
---
ARVN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ARVN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 11, 2025 | $18.97 | $17.68 | -6.80% |
| Oct 30, 2024 | $27.50 | $27.66 | +0.58% |
| Jul 30, 2024 | $27.78 | $27.09 | -2.48% |
| May 07, 2024 | $32.26 | $34.33 | +6.42% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Arvinas Holding Company (ARVN) report earnings?
Arvinas Holding Company (ARVN) is schdueled to report earning on May 06, 2025, TBA Not Confirmed.
What is Arvinas Holding Company (ARVN) earnings time?
Arvinas Holding Company (ARVN) earnings time is at May 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ARVN EPS forecast?
ARVN EPS forecast for the fiscal quarter 2025 (Q1) is -1.02.
---